Bioprocess miniaturization: Development and optimisation
Tuesday 26th November 2013
Cineworld: The O2, London, SE10 0DX, UK
Miniaturisation and automation of bioprocess development continues to be a rapidly expanding area of interest since the technologies promise to reduce biopharmaceutical development time and cost. This meeting will focus on recent technologies used in high throughput bioprocess development, from clone selection through to analysis of final product and formulation. Expert speakers will describe the development and use of current miniaturisation technologies together with the technical and regulatory hurdles that must be overcome to facilitate wider industrial uptake.
This event has CPD accreditation and is part of The 2013 BioProcessing Summit – www.BioprocessingSummit2013.com
Meeting chair: Professor. Chris Lowe, Department of Chemical Engineering and Biotechnology, University of Cambridge, UK
Who Should Attend:
Biotech and Pharma Industry: CEOs, Chief Scientists, Group Heads, Senior and Junior Scientists, Research Managers
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
The deadline for abstract submissions for oral presentation has now passed. Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talk times include 5 – 10 minutes for questions
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair: Professor. Chris Lowe, Department of Chemical Engineering and Biotechnology, University of Cambridge, UK
10:00 – 10:30 Confinement phenomenon based bio-process intensification using monolithic microreactors
Professor Galip Akay, School of Chemical Engineering and Advanced Materials, Newcastle University, UK
Bio-Process intensification, B-PI (by a factor of 5-200 fold compared with batch processing) is achievable using monolithic microreactors with well defined physical and biochemical structure of pores used as support for bacteria or cells. This enhancement is due to ‘confinement phenomenon’ in which the behaviour of microorganisms is dependent on their confining environment. Recent examples of B-PI pioneered at Newcastle University include fermentation, antibiotics and enzyme production as well as tissue engineering and Agri-Process Intensification through bacterial nitrogen fixation by plants. Mechanism of B-PI will be discussed.
10:30 – 11:00 Microfluidic BioLector – A new microbioreactor platform with continuous pH-control and substrate feeding
Dr. Frank Kensy and Dr. Christian Hetzel, m2p-labs GmbH/Inc., Germany/USA
Today bioprocess development is mainly performed in lab-scale stirred tank bioreactors due to controlled process conditions provided by these reactors. Even if several microbioreactor concepts have been established so far in industry to fulfill the demand of high-throughput and ease of use, these technologies are mainly applied in clone screening and media development due to the lack of pH-control and feeding. Therefore, m2p-labs amplified the spectrum of their microbioreactor technology, BioLector®, towards pH-control and continuous feeding options. A user-friendly, disposable microfluidic bioreactor system was created that allows scalable, fully monitored and fully controlled fermentations at micro-scale.
11:00 – 11:30 Speakers’ photo then mid-morning break and poster exhibition and trade show
11:30 – 12:00 Lyophilised Biopharmaceticals- Looking at Cake Properties
Dr Daryl R Williams, Director of Development, Discovery Space and Reader in Particle Science, Department of Chemical Engineering, Imperial College, UK
An innovative method for the mechanical testing of freeze-dried biopharmaceutical cakes in situ vials has been developed. This simple and quick compression test allows a range of cake mechanical properties to be assessed quantitatively. It can be readily applied to fragile and moisture sensitive freeze-dried cakes within the vials. Freeze dried mannitol, sucrose and trehalose samples all yielded linear compressive elastic behavior for small strains with Young’s Moduli of 25, 120 and 170 kPa respectively. This method discriminates readily between the three excipients reported here and can be used to optimise formulation of biopharmaceutical systems.
12:00 – 12:30 Oral Presentations:
UP-SCALING FROM A MICRO- TO A LAB-SCALE BIOREACTOR BY APPLYING THE FED-BATCH MODE AT BOTH SCALES
Csilla Török, ACIB GmbH – Austrian Centre of Industrial Biotechnology; c/o University of Natural Resources and Life Sciences, A-1190 Vienna, Austria; Monika Cserjan, Department of Biotechnology, University of Natural Resources and Life Sciences, A-1190 Vienna, Austria; Gerald Striedner, Department of Biotechnology, University of Natural Resources and Life Sciences, A-1190 Vienna, Austria;
12:30 – 13:30 Lunch, poster exhibition and trade show
13:30 – 14:30 Discussion session
This discussion session is an informal question and answer session. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.
There are three ways you can ask questions:
1. Before the session you can submit your question to Euroscicon staff at the registration desk,
2. Before and during the session you can submit a question or comments, by email, which will be provided on the day of the event
3. During the session you can put your hand up and join in
14:30 – 15:00 ambr™ and ambr250™: advanced tools for automated optimization and process development in both microbial and cell cultures for application in biotherapeutics and industrial biotechnology
Mr Mwai Ngibuini, Bioprocess product specialist, TAP Biosystems, UK
Exploration of a large number of cell lines or microbial strain candidates, as well as developing optimal process pathways requires the application DOE analysis with a suitable power number. Traditionally these campaigns require large laboratory space, and are both costly and labour intensive. TAP Biosystems has developed the advanced microbioreactor (ambr™) that is widely adopted as a rapid cell line selection and early stage cell culture optimization tool. As well as, the ambr250™, a tool that is being used for microbial strain selection, process optimization and late stage cell culture optimization. Here we present a technology overview and industry derived data.
15:00 – 15:30 Afternoon Tea, last poster session and trade show
15:30 – 16:00 Introducing: micro-Matrix, the next generation in microbioreactors
Mr Martijn Kreukniet, Product Manager, Applikon Biotechnology, UK
Applikon biotechnology specializes in development, manufacturing and marketing of bioreactor systems from production scale to laboratory scale. What are the trends and the challenges in the market when scaling down, what are the currently available solutions and where do we see the new developments take us? What is the current volume limit of the commercial small-scale bioreactors and why. Applikon offers systems down to 200 microliter volume. When scaling down to this volume the main process parameters should be maintained. Oxygen supply, mixing, nutrient supply are just a few parameters but also sample volume for proper analysis is important. Time to setup an experiment is another factor that will determine the success of a small-scale system. When a successful mini or micro bioreactor is developed and operational, the next challenge is to cope with the large amount of process data that will be generated by these systems. How can we make it easier to define multiple experiments and to interpret the experimental data. This presentation will aim to give an overview of the bioreactor market in general with a focus on the scale down market.
16:00 – 16:30 Talk title to be confirmed
Dr Martina Micheletti, The Advanced Centre for Biochemical Engineering, University College London, UK
16:30 – 17:00 Chairman’s summing up
Registration Website: http://www.regonline.co.uk/Mini2013
About the Chair:
Chris Lowe‘s group’s primary research interest is in healthcare biotechnology, particularly where it is applied to the high-value low-volume sectors of biopharmaceuticals, sensors and diagnostics and microbial technology. The work is highly multidisciplinary and not only covers aspects of molecular biology, biochemistry, microbiology, chemistry, physics, electronics and engineering, but also the entire range from fundamental science to strategic and applied science, much of which has significant commercial application.
About the Speakers:
Galip Akay holds the established chair of Chemical Engineering at Newcastle University. He has a multi-disciplinary education and research background both in academia and industry. He is one of the founders of Process Intensification in chemical technology. More recently, he extended this discipline to biotechnology, tissue engineering and agriculture through the discovery of the ‘confinement phenomenon’. His research in energy and materials science is commercialised by 3 spin-out companies in collaboration with international companies. He has some 250 publications and over 70 patents. He is a founding trustee of the UK Children’s Neurological Research Campaining.
Frank Kensy studied Biochemical Engineering at the University Essen, Madrid and at RWTH Aachen. After receiving his diploma, he first started his professional career as fermentation scientist for new recombinant enzymes and pharmaceutical proteins at Rhein Biotech N.V. in Düsseldorf. In 2002 he decided to return to RWTH Aachen University for doing his PhD on shaken microbioreactors with Prof. Jochen Büchs. Since November 2005 he is founder and managing director of m2p-labs responsible for R&D and sales.
Daryl R. Williams has a B.Sc.(Hons) from University of Melbourne, Australia, a M.Sc. from Lehigh University, USA before completing his Ph.D at Imperial College London where he is the Reader in Particle Science. Daryl has published over 70 journal papers, has 5 patents and is a world leader in advanced instrumental characterisation of solids. He is the founder of Surface Measurement Systems. He researches the surface/bulk characterisation of organic solids including biopharmaceutics, as well as their manufacture using spray and freeze drying, crystallisation, freeze drying, milling and granulation. Sponsors include EPSRC, BBSRC, Pfizer, Astra-Zeneca, P&G, BTL, Avecia and GSK.
Mwai Ngibuini is the ambr250 bioprocess product specialist at TAP Biosystems, prior to joining TAP Mwai had over ten years upstream bioprocessing experience working in both biopharm and industrial biotechnology where he worked with a wide range of microbial strain. Mwai Ngibuini completed a BEng in Chemical engineering at London South Bank University and then studied for an MSc in Biochemical engineering at University College London graduating at 2003. His area of interest is Bioreactor technology.
Martijn Kreukniet is a product manager at Applikon Biotechnology B.V. in Delft, the Netherlands. He received his bachelor degree in Biotechnology at the Rotterdam University in 2000 and has since been involved in field of industrial biotechnology. His work at Applikon and natural interest to know more, has given him a broad knowledge in the field of sensor technologies and small-scale bioreactors.
Post expires at 3:58pm on Tuesday November 26th, 2013